TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Swedish cohort study of older women found that longer reproductive lifespan and reported menopausal hormone therapy use were associated with more favorable measures of brain vascular health on MRI. The observational findings do not show that estrogen exposure caused those differences or establish that hormone therapy prevents dementia.
A Swedish study of 352 cognitively unimpaired women found that longer reproductive lifespan and reported menopausal hormone therapy use were associated with lower cerebral small vessel disease burden and other more favorable brain MRI measures at age 70. The findings, reported by Anna Marseglia of the Karolinska Institutet and colleagues in Neurology, show an association, not proof that estrogen exposure protects the brain or prevents dementia.
The researchers calculated reproductive lifespan from the age participants began menstruating to the age of menopause or ovary removal. On average, it was 37.1 years. Each longer reproductive span was associated with 8% lower odds of having two or more signs of cerebral small vessel disease (odds ratio 0.92; 95% confidence interval 0.86 to 0.99), the study reported.
Menopausal hormone therapy use was associated with lower odds of greater small vessel disease burden (odds ratio 0.41; 95% confidence interval 0.20 to 0.81) and higher white matter integrity. Women who reported using oral contraceptives earlier in life and hormone therapy later had the lowest measured small vessel disease burden and the greatest white matter integrity in the analyses. These are statistical associations within this cohort, not estimates of treatment effects for an individual.
The study also reported that, among participants who carried an APOE4 genetic variant associated with Alzheimer’s risk, hormone therapy use was linked with greater thickness in brain regions commonly affected by Alzheimer’s disease. About 31% of the women were APOE4 carriers. Researchers assessed brain structure using MRI measures that included white matter changes, small areas of tissue damage and other markers; they did not report that participants had been diagnosed with dementia.
Brain Vascular Measures in Older Women
The results add to research examining whether reproductive and hormone histories are relevant to brain aging. The study looked at vascular brain measures as well as Alzheimer’s-related imaging, broadening attention beyond dementia diagnoses alone. Cerebral small vessel disease can be assessed through MRI findings, but this study does not show that the observed differences led to better memory or reduced future dementia.
That distinction matters for readers weighing claims about menopausal hormone therapy. The findings may help researchers identify questions for larger or longer studies, but they do not establish that starting hormone therapy improves brain health, nor do they settle the treatment’s benefits and risks. Treatment decisions depend on individual circumstances and should be discussed with a qualified health professional.
Popular right now
Ninja SP151 Flip Toaster Oven and Air Fryer
iRobot Roomba 105 Robot Vacuum with LiDAR Navigation
Philips Café Aromis Automatic Espresso Machine with LatteGo Pro Milk System
As an affiliate, we earn on qualifying purchases.
A Small Gothenburg Cohort
The participants came from Sweden’s 1944 Gothenburg H70 birth cohort. All 352 women were cognitively unimpaired at the age-70 assessment and had brain MRI; 286 returned for a follow-up examination five years later. Their average score on the Mini-Mental State Examination was 29.2 at baseline, consistent with generally intact performance on that screening test.
Most participants reported oral contraceptive use (72.7%), and 60.8% reported menopausal hormone therapy use. The study sits within a complicated history of hormone research. The Women’s Health Initiative Memory Study reported in 2003 that estrogen-plus-progestin treatment increased probable dementia risk among women aged 65 or older, while the broader trial associated the combined treatment with higher breast cancer and heart disease risks. The FDA removed the boxed warning from menopausal hormone therapy in 2026, according to the source report; that regulatory change does not itself establish a brain-health benefit.
Earlier observational research has also examined estrogen-only therapy and the timing of hormone treatment. Such studies differ in populations, treatments and methods, so they do not by themselves resolve the questions raised by the older clinical trial findings.
“The lifetime risk of dementia in U.S. women exceeds that of men.”
— Tracy Madsen, MD, PhD, University of Vermont, in an accompanying editorial
Limits of the Hormone Evidence
The study cannot determine whether hormone exposure caused the MRI differences. Participants reported their past use of oral contraceptives and menopausal therapy, leaving the data vulnerable to recall errors and misclassification. The researchers also lacked detailed information about treatment duration and specific formulations, limiting comparisons between types and patterns of use.
The cohort was modest in size and drawn from one Swedish birth group. Most participants were cognitively unimpaired at baseline, and the reported outcomes were brain imaging measures rather than a demonstration that treatment prevented dementia. The findings also do not establish whether associations apply to other ages, populations or hormone regimens. The source report does not provide evidence that the observed MRI associations translate into a clinical benefit.
Further Study of Timing and Outcomes
The immediate next step is replication in larger and more diverse groups, with clearer records of hormone type, dose, timing and duration. Longer follow-up could test whether the MRI patterns are associated with later changes in cognition or dementia diagnoses, rather than imaging measures alone.
For now, the study adds an observational finding to a mixed evidence base. Researchers, clinicians and patients will need evidence that separates the effects of reproductive lifespan from other health and social factors before drawing conclusions about hormone therapy and brain disease. No treatment recommendation follows from this cohort report.
Key Questions
Did the study show that estrogen prevents dementia?
No. It found associations between reproductive or hormone-treatment history and brain MRI measures. It did not establish cause and effect or show that estrogen prevents dementia.
How many women took part?
The study included 352 cognitively unimpaired women from a Swedish cohort, all assessed with MRI at age 70. A total of 286 took part in a follow-up exam five years later.
What did researchers mean by reproductive lifespan?
They calculated it by subtracting the age at first menstruation from the age at menopause or ovary removal. The cohort’s average reproductive lifespan was 37.1 years.
Can the findings guide an individual’s hormone therapy decision?
The study does not establish a brain-health benefit or provide treatment advice. People considering menopausal hormone therapy should discuss personal benefits and risks with a qualified health professional.
Source: medpagetoday.com
